For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Acetylon Pharmaceuticals, Inc.

USPTO Granted Patents = 35

% Expired Patents = 8.6

CIPO Patents = 2

EPO Patents = 17

Forward Citations = 277

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

John Henry Van Duzer (18 out of 55 patents)

Ralph Mazitschek (16 out of 63 patents)

Steven N Quayle (11 out of 11 patents)

4. Simon Stewart Jones (10 out of 10 patents)

5. Min Yang (6 out of 6 patents)

6. Nan Yu (6 out of 6 patents)

7. David Lee Tamang (4 out of 4 patents)

8. James Bradner (4 out of 25 patents)

9. Guoxiang Huang (4 out of 11 patents)

10. Dejian Xie (4 out of 5 patents)

11. Walter Ogier (4 out of 4 patents)

12. Teru Hideshima (3 out of 14 patents)

13. Chengyin Min (3 out of 3 patents)

14. Kenneth Carl Anderson (3 out of 40 patents)

15. Yun Cao (2 out of 9 patents)

35 patents: Sort by Forward Citations

1. 12053468 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2024-08-06),

2. 11998546 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof (2024-06-04),

3. 11872227 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof (2024-01-16),

4. 11813261 - HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia (2023-11-14),

5. 11666568 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof (2023-06-06),

6. 11617750 - Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof (2023-04-04),

7. 11497746 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof (2022-11-15),

8. 11357776 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof (2022-06-14),

9. 11337975 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2022-05-24),

10. 11324744 - Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies (2022-05-10),

11. 11311540 - Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs (2022-04-26),

12. 11298354 - Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors (2022-04-12),

13. 10927072 - Phenyl and pyridinyl hydroxamic acids (2021-02-23),

14. 10722512 - Combinations of histone deacetylase inhibitors and either HER2 inhibitors or PI3K inhibitors (2020-07-28),

15. 10648038 - Biomarkers to identify patients that will respond to treatment and treating such patients (2020-05-12),

Acetylon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of selective histone deacetylase (HDAC) inhibitors for the treatment of cancer and other diseases. Their mission is to develop innovative therapies that target protein acetylation, a key process in cellular regulation. With a diverse pipeline and a commitment to scientific excellence, Acetylon Pharmaceuticals strives to improve patients' lives through their research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Acetylon Pharmaceuticals, Inc.

35 Patents

#68 in Boston, MA

#582 in Massachusetts

#9,734 in US

#19,126 in the World

Boston, MA, United States of America

Acetylon Pharmaceuticals, Inc.

Forward Citations = 277

29 inventors:

John Henry Van Duzer (18 out of 55 patents)

Ralph Mazitschek (16 out of 63 patents)

Steven N Quayle (11 out of 11 patents)

4. Simon Stewart Jones (10 out of 10 patents)

5. Min Yang (6 out of 6 patents)

Please report any incorrect information to [email protected]

Loading…